Dr Frank Dieterle
Dr Frank Dieterle is the project co-leader in the BRCCH-funded DAVINCI project. He received a PhD in Bioinformatics and Analytics from the University of Tübingen in 2003. He joined Roche in 2003 building up the Metabolomics research. His research interests are in-vitro diagnostics (IVD), companion diagnostics, biomarkers, nephrology and machine learning
In 2005 Dr Dieterle joined Novartis as project leader of safety biomarkers and was co-founder and first director of the international IMI SAFE-T consortium. In parallel, Dr Dieterle was global project team representative for Translational Medicine in 2 drug development programs in transplantation and nephrology. He joined the newly created Novartis Companion Diagnostics department bringing companion diagnostic tests from research to the market. In 2012 he became part of a small team leading the acquisition of the biotech VIVACTA and building up the Novartis Near Patient Testing Unit and a new Novartis site in Kent. In 2016 the unit launched and commercialized the first Novartis point of care IVD platform NIJI and diagnostic tests. Dr Dieterle led the Novartis Kent site 2017-2018 and the NPT unit until its closure.
In 2019 Dr Dieterle joined part-time FHNW (University of Applied Sciences and Arts, Northwestern Switzerland) for the scientific project leadership of the biotech Genuine Analytics AG. Dr Dieterle is co-founder and CSO of the startup Mulier Health GmbH and CEO of Dieterle Life Science Consulting. In 2020 Dr Dieterle took the initiative to assemble members of the M4IVD network to develop home tests for COVID-19 which was the birth of the DAVINCI consortium.